Participants:0–17 years · 18–64 years
Substances:Autologous Cd34+ Cells Transduced With The G1Xcgd Lentiviral Vector Containing The Human Cybb Gene
Sponsor:Genethon

Contact Research Centre

Chronic lymphocytic leukaemia

Not recruiting

Registered drugNo placebo

Study on Obinutuzumab, Chlorambucil, and Acalabrutinib for Patients with Untreated Chronic Lymphocytic Leukemia

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Acalabrutinib
Sponsor:Acerta Pharma B.V.

Contact Research Centre

Acute myeloid leukaemia

Not recruiting

Registered drugNo placebo

Study of Cusatuzumab and Azacitidine for Patients with Newly Diagnosed Acute Myeloid Leukemia Not Eligible for Intensive Chemotherapy

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Azacitidine
Sponsor:OncoVerity Inc.

Contact Research Centre

Thrombotic thrombocytopenic purpura

Not recruiting

Registered drugNo placebo

Study on Caplacizumab and Immunosuppressive Therapy for Adults with Immune-Mediated Thrombotic Thrombocytopenic Purpura

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Caplacizumab
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Plasma cell myeloma

Not recruiting

Registered drugNo placebo

Study of Durbactagene Autoleucel and Drug Combination for Adults with Relapsed and Refractory Multiple Myeloma

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Bendamustine
Sponsor:Novartis Pharma AG

Contact Research Centre

Warm autoimmune haemolytic anaemia

Not recruiting

Registered drug

Study of ianalumab versus placebo in adults with warm autoimmune hemolytic anemia who failed previous treatment

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Danazol
Sponsor:Novartis Pharma AG

Contact Research Centre

Acute myeloid leukaemia

Not recruiting

Registered drug

Study of Venetoclax and Azacitidine for Patients with Untreated Acute Myeloid Leukemia Who Cannot Have Standard Induction Therapy

Registered drug

Belgium

Participants:18–64 years · 65+ years
Substances:Azacitidine
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Immune thrombocytopenia

Not recruiting

Registered drugNo placebo

Study Comparing Romiplostim and Dexamethasone with Dexamethasone Alone for Patients with Newly Diagnosed Primary Immune Thrombocytopenia

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Romiplostim
Sponsor:Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De Sevilla

Contact Research Centre

Diffuse large B-cell lymphoma+2

Not recruiting

Registered drug

Study on Golcadomide and R-CHOP Drug Combination for Patients with Untreated High-risk Large B-cell Lymphoma

Registered drug

Austria

Participants:18–64 years · 65+ years
Substances:Apixaban
Sponsor:Celgene Corp.

Contact Research Centre

Plasma cell myeloma refractory

Not recruiting

Registered drugNo placebo

Study Comparing Teclistamab with Daratumumab, Pomalidomide, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Bortezomib
Sponsor:Janssen Cilag International

Contact Research Centre

Sickle cell disease

Not recruiting

Investigational

Study on the Effects of Etavopivat for Patients Aged 12-65 with Sickle Cell Disease

Investigational

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Etavopivat
Sponsor:Novo Nordisk A/S

Contact Research Centre

Substances studied in this area

The therapies tested most often in Blood and lymphatic system disorders trials.

Dexamethasone139 clinical trials Rituximab122 clinical trials Venetoclax114 clinical trials Cyclophosphamide100 clinical trials Lenalidomide98 clinical trials Cytarabine77 clinical trials Daratumumab74 clinical trials Azacitidine65 clinical trials Bortezomib64 clinical trials

Blood and lymphatic system disorders – page 86

Conditions in this area

Clinical trials in Blood and lymphatic system disorders

1 201 clinical trials

Polycythaemia vera

Study on the Effects of Sapablursen for Patients with Phlebotomy Dependent Polycythemia Vera

Chronic granulomatous disease

Study of G1XCGD Lentiviral Vector in Patients with X-Linked Chronic Granulomatous Disease

Chronic lymphocytic leukaemia

Study on Obinutuzumab, Chlorambucil, and Acalabrutinib for Patients with Untreated Chronic Lymphocytic Leukemia

Acute myeloid leukaemia

Study of Cusatuzumab and Azacitidine for Patients with Newly Diagnosed Acute Myeloid Leukemia Not Eligible for Intensive Chemotherapy

Thrombotic thrombocytopenic purpura

Study on Caplacizumab and Immunosuppressive Therapy for Adults with Immune-Mediated Thrombotic Thrombocytopenic Purpura

Plasma cell myeloma

Study of Durbactagene Autoleucel and Drug Combination for Adults with Relapsed and Refractory Multiple Myeloma

Warm autoimmune haemolytic anaemia

Study of ianalumab versus placebo in adults with warm autoimmune hemolytic anemia who failed previous treatment

Acute myeloid leukaemia

Study of Venetoclax and Azacitidine for Patients with Untreated Acute Myeloid Leukemia Who Cannot Have Standard Induction Therapy

Immune thrombocytopenia

Study Comparing Romiplostim and Dexamethasone with Dexamethasone Alone for Patients with Newly Diagnosed Primary Immune Thrombocytopenia

Diffuse large B-cell lymphoma+2

Study on Golcadomide and R-CHOP Drug Combination for Patients with Untreated High-risk Large B-cell Lymphoma

Plasma cell myeloma refractory

Study Comparing Teclistamab with Daratumumab, Pomalidomide, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Sickle cell disease

Study on the Effects of Etavopivat for Patients Aged 12-65 with Sickle Cell Disease

Filter the trials

Substances studied in this area

Prefer not to search? Our Concierge searches the trials for you.